Earnings summaries and quarterly performance for CHAMPIONS ONCOLOGY.
Executive leadership at CHAMPIONS ONCOLOGY.
Board of directors at CHAMPIONS ONCOLOGY.
Research analysts who have asked questions during CHAMPIONS ONCOLOGY earnings calls.
GM
George Marema
Pareto Ventures
4 questions for CSBR
Also covers: ASYS, DAIO, FEIM
CH
Clay Hoffman
Hoffman
3 questions for CSBR
MH
Matthew Hewitt
Craig-Hallum Capital Group LLC
2 questions for CSBR
Also covers: ACET, APYX, BHST +21 more
MH
Matt Hewitt
Craig-Hallum Capital Group
2 questions for CSBR
Also covers: NOTV, SLP
RB
Richard Baffarin
Private Investor
2 questions for CSBR
JC
Jack Christopher Siedow
Craig-Hallum Capital Group LLC
1 question for CSBR
MS
Maj Soueidan
GeoInvesting
1 question for CSBR
Also covers: TSSI
TK
Tol Kohrman
Craig-Hallum
1 question for CSBR
TK
Tollef Kohrman
Craig-Hallum Capital Group LLC
1 question for CSBR
TK
Tov Kormanon
Craig-Hallum Capital Group
1 question for CSBR
Recent press releases and 8-K filings for CSBR.
CSBR Reports Q2 2026 Financial Results with 11% Revenue Growth
CSBR
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- CSBR reported Q2 2026 revenue of $15 million, an 11% year-over-year increase from $13.5 million, driven by improved conversion of booked work due to lower cancellations.
- The company achieved a gross margin of 52% in Q2 2026, up from 45% last year, and approximately $800,000 in Adjusted EBITDA, remaining on track for full-year positive Adjusted EBITDA for fiscal 2026.
- Strategic investments are focused on enhancing the data platform and expanding radiolabeling capabilities, which are identified as key long-term value drivers and are expected to improve gross margins as more work is brought in-house.
- CSBR is making solid progress in discussions for venture capital funding for its subsidiary, Corelia, with plans to redirect investment towards accelerating growth in the data business once external funding is secured. The company ended the quarter with $8.5 million in cash and no debt.
Dec 15, 2025, 9:30 PM
Champions Oncology Reports Q2 2026 Financial Results
CSBR
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- Champions Oncology (CSBR) reported Q2 2026 revenue of $15 million, an 11% year-over-year increase from $13.5 million, primarily driven by improved conversion of booked work due to a reduction in cancellations.
- For the quarter, the company achieved an income from operations of $185,000 and approximately $800,000 in Adjusted EBITDA, with a gross margin of 52% compared to 45% in the prior year.
- CSBR is on track to meet its fiscal 2026 goals of delivering year-on-year revenue growth and full-year positive Adjusted EBITDA, while continuing strategic investments in its data platform and specialized radiolabeling capabilities.
- Operating expenses for the quarter increased by about $2 million year-over-year to $7 million, mainly due to investments in R&D for the data platform, sales and marketing to strengthen the commercial organization, and G&A related to leadership transitions and IT infrastructure.
Dec 15, 2025, 9:30 PM
Champions Oncology Reports Q2 Fiscal 2026 Financial Results
CSBR
Earnings
Guidance Update
New Projects/Investments
- Champions Oncology (CSBR) reported Q2 Fiscal 2026 revenue of $15 million, marking an 11% year-over-year increase from $13.5 million, primarily due to improved conversion of booked work and reduced cancellations.
- The company achieved income from operations of $185,000 and approximately $800,000 in Adjusted EBITDA for the quarter, with gross margin improving to 52% compared to 45% in the prior year.
- Strategic investments continued in its data platform and radiolabeling capabilities, with the latter expected to become an increasingly meaningful service offering and improve gross margins as work is brought in-house.
- Champions Oncology remains committed to and on track to deliver year-over-year revenue growth and full-year positive Adjusted EBITDA for fiscal 2026, maintaining a solid financial position with $8.5 million in cash and no debt.
- Discussions are underway with potential venture capital funding partners for Corelia, its wholly-owned target discovery subsidiary, which will continue to be reflected in the P&L until external funding is secured.
Dec 15, 2025, 9:30 PM
Champions Oncology Reports Q1 FY2026 Results and CEO Transition
CSBR
Earnings
Management Change
New Projects/Investments
- Champions Oncology reported Q1 fiscal year 2026 revenue of $14 million, which was flat compared to the first quarter of last year but represented a solid rebound from the $12.4 million reported in Q4.
- The company recorded an operating loss of $0.5 million for Q1 2026, but achieved $60,000 in adjusted EBITDA.
- Rob Brennan stepped into the role of Chief Executive Officer and emphasized continued expansion of the core TOS platform, and driving value in Corellia and the data business.
- Champions Oncology ended Q1 2026 with $10.3 million in cash, remains debt-free, and generated $0.6 million in positive operating cash flow.
- Management anticipates sequential revenue growth, continued profitability on an adjusted EBITDA basis, and margin expansion in the second half of fiscal year 2026, as radiolabeling work shifts in-house.
Sep 15, 2025, 8:30 PM
Champions Oncology Q3 2025 Record Revenue & Earnings Highlights
CSBR
Earnings
Revenue Acceleration/Inflection
Guidance Update
- Champions Oncology, Inc. reported record Q3 2025 revenue of $17.0 million (a 42% increase), with record adjusted EBITDA of $5.2 million and GAAP operating income/net income of approximately $4.5 million
- Data Licensing Initiative: Secured its first major, one-time data licensing deal valued up to $8.0 million, contributing $4.5 million in data revenue
- Operational Efficiency and Guidance: Improved cost management and research services boosted performance to achieve 61% gross margins, ending the quarter with $3.2 million in cash and no debt, while reaffirming full-year revenue growth guidance of 10%-15%
Mar 11, 2025, 12:00 AM
Quarterly earnings call transcripts for CHAMPIONS ONCOLOGY.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more